medigraphic.com

2023, Number 1

<< Back Next >>

Rev Mex Anest 2023; 46 (1)

Malignant hyperthermia

Ortiz-Bautista JG, Colín-Hernández J, León-Álvarez E

Language: Spanish
References: 27
Page: 38-45
PDF size: 278.85 Kb.


ABSTRACT

Malignant hyperthermia is a rare, life-threatening pharmacogenetic disorder which presents as a hypermetabolic response to volatile anesthetics and depolarizing muscle relaxants in susceptible individuals. This susceptibility is associated with mutations in three genes: RYR1, CACNA1S and STAC3. Can manifest with mild symptoms or as a fulminant crisis, with severe rhabdomyolysis, ventricular fibrillation and acute renal and circulatory failure, therefore the prognosis depends on how soon the diagnosis is suspected and how fast treatment is started. The definitive diagnosis is based on a fresh muscle biopsy sensitivity test and genetic testing. The best way to prevent an event is the early detection of susceptible, as well as have equipment to respond to a crisis in each center where volatile anesthetics are administered and the training of staff. This review synthesizes current clinical and biomedical concepts for detection, prevention, diagnosis and management of malignant hyperthermia.


REFERENCES

  1. Kaur H, Katyal N, Yelam A, Kumar K, Srivastava H, Govindarajan R. Malignant hyperthermia. Mo Med. 2019;116:154-159.

  2. Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355-362.

  3. Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168-180.

  4. Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology. 2018;128:159-167.

  5. Dalmas A, Roux-Buisson N, Julien-Marsollier F, Bosson C, Bruneau B, Payen JF, et al. Hipertermia maligna de la anestesia. EMC-Anestesia-Reanimación. 2019;45:1-12. doi: 10.1016/S1280-4703(19)42971-X.

  6. Biesecker LG, Dirksen RT, Girard T, Hopkins PM, Riazi S, Rosenberg H, et al. Genomic screening for malignant hyperthermia susceptibility. Anesthesiology. 2020;133:1277-1282.

  7. McCarthy TV, Healy JM, Heffron JJ, Lehane M, Deufel T, Lehmann-Horn F, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990;343:562-564.

  8. Stamm DS, Powell CM, Stajich JM, Zismann VL, Stephan DA, Chesnut B, et al. Novel congenital myopathy locus identified in Native American Indians at 19q13.13-14.1. Neurology. 2008;71:1764-1769.

  9. Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anaesth. 2018;65:709-721.

  10. Gupta P, Hopkins P. Diagnosis and management of malignant hyperthermia. BJA Education. 2017;17:249-254.

  11. Brandom BW, Callahan PM. Malignant hyperthermia: an update. Advances in Anesthesia. 2015;33:113-128.

  12. Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021;76:655-664.

  13. Yang L, Tautz T, Zhang S, Fomina A, Liu H. The current status of malignant hyperthermia. J Biomed Res. 2019;34:75-85.

  14. Heytens L, Forget P, Scholtes JL, Veyckemans F. The changing face of malignant hyperthermia: less fulminant, more insidious. Anaesth Intensive Care. 2015;43:506-511.

  15. Ellinas H, Albrecht MA. Malignant hyperthermia update. Anesthesiol Clin. 2020;38:165-181.

  16. Gleich SJ, Strupp K, Wilder RT, Kor DJ, Flick R. An automated real-time method for the detection of patients at risk for malignant hyperthermia. Paediatr Anaesth. 2016;26:876-882.

  17. Gray RM. Anesthesia-induced rhabdomyolysis or malignant hyperthermia: is defining the crisis important? Paediatr Anaesth. 2017;27(5):490-493.

  18. Spruce L. Malignant hyperthermia. AORN J. 2020;112:281-290.

  19. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771-779.

  20. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. doi: 10.1186/s13023-015-0310-1.

  21. Carrillo ER, Lázaro SG, Nava LJA. Hipertermia maligna: Conceptos actuales. Rev Mex Anest. 2013;36:185-192.

  22. Hara Y, Hosoya Y, Deguchi R, Sawamura S. A case of malignant hyperthermia that was difficult to be differentiated from oral antipsychotic polypharmacy-associated neuroleptic malignant syndrome. JA Clin Rep. 2016;2:8. doi: 10.1186/s40981-016-0035-8.

  23. Ortiz JF, Wirth M, Eskander N, Cozar JC, Fatade O, Rathod B. The genetic foundations of serotonin syndrome, neuroleptic malignant syndrome, and malignant hyperthermia: is there a genetic association between these disorders? Cureus. 2020;12:e10635.

  24. Larach MG, Rosenberg H, Gronert GA, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila). 1997;36:9-16.

  25. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg. 2009;109:1049-1053.

  26. Safety Committee of Japanese Society of Anesthesiologists. JSA guideline for the management of malignant hyperthermia crisis 2016. J Anesth. 2017;31:307-317.

  27. Malignant Hyperthermia Association of the Unites States. 2022. Available in: http://www.mhaus.org}




2020     |     www.medigraphic.com